ovarian-cancer

Documents about ovarian-cancer

• Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65).#831671ClinicalTrials.gov
• Comparison of the effect of Sonidegib and Vismodegib on Paclitaxel resistant ovarian cancer cell lines.#228256RepOD Dataverse OAI Archive
• Evaluation of 68Ga-FAPI-46 and 18F-FDG PET/CT Imaging for Detecting Recurrent Tumor Lesions in Patients of Ovarian Cancer#839140ClinicalTrials.gov
• Feasibility of Lifestyle Intervention in BRCA1/2 Mutation Carriers#849153ClinicalTrials.gov
• Mirena® IUD's Effect on Fallopian Tube Fimbriae and Ovarian Cortical Inclusion Cyst Cell Proliferation#893672ClinicalTrials.gov
• A Single-arm Clinical Trial of IMGN853 in Chinese Adult Patients With Platinum-resistant, Epithelial Ovarian Cancer#831793ClinicalTrials.gov
• Clinical Characters of the Diagnosis and Treatment of Gynecological Malignant Tumors in China : A Real World Study#451497ClinicalTrials.gov
• Guilford Genomic Medicine Initiative (GGMI)#812471ClinicalTrials.gov
• Study to Evaluate PM01183 in Combination With Olaparib in Advanced Solid Tumors#827250ClinicalTrials.gov
• MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer#825086ClinicalTrials.gov
• Integrated Care Pathway in Oncology (PASSION)#902625ClinicalTrials.gov
• A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer#918170ClinicalTrials.gov
• Ovarian-Sparing Adaptive Radiotherapy in Young Adult Women#910017ClinicalTrials.gov
• Virtual Mental Health Intervention to Address Fear of Progression for Women With High Risk or Stage III-IV Gynecologic or Breast Cancer#966956ClinicalTrials.gov
• Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer#827648ClinicalTrials.gov
• Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability#882251ClinicalTrials.gov
• Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial#467610ClinicalTrials.gov
• Michigan Genetic Hereditary Testing (MiGHT)#906879ClinicalTrials.gov
• Optional Sub-study to Intraoperative Imaging With ICG Registry#843472ClinicalTrials.gov
• Biomarkers in Patients With Previously Untreated Invasive Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer#831665ClinicalTrials.gov
• Patient Blood Mangement (PBM) Using IV Iron in Patients With Gynecologic Cancer#832691ClinicalTrials.gov
• Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer#849590ClinicalTrials.gov
• Perioperative dynamics of siglec-15 and soluble PD-L1 in ovarian cancer surgery: Influence of anaesthetic technique on immune regulation#414196African Journals Online
• TRIal evalUating the Menstrual and Ovarian Function of Young Breast Cancer Patients Treated With a cycloPHosphamide-free Regimen#831811ClinicalTrials.gov
• Proactive Immune Tolerance Induction in Chemotherapy for Gynecologic Cancer#827849ClinicalTrials.gov
• A Phase 1b Study of Paclitaxel And Ricolinostat For The Treatment Of Gynecological Cancer#849880ClinicalTrials.gov
• Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies#844649ClinicalTrials.gov
• Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors#811070ClinicalTrials.gov
• Anti-PD-L1 and SAbR for Ovarian Cancer#674896ClinicalTrials.gov
• HIPEC After Initial CRS in Patients Who Have Received NACT#863067ClinicalTrials.gov
• Prospective Multicenter Study in Patients With a Tumor Benign Ovarian Presumed on the Use of Algorithms Such as Roma and RMI and Tumor Markers Such as CA125 and HE4#844544ClinicalTrials.gov
• PARP16 is a Druggable Regulator of Ribosome MARylation and Protein Homeostasis in Ovarian Cancer Cells#150382bioRxiv / medRxiv
• Systems serology of responses against tumor antigens in ovarian cancer reveal disrupted Fc-mediated immunity#234314bioRxiv / medRxiv
• Female Fertility Preservation Using Ovarian Tissue Cryopreservation Before Highly Gonadotoxic Cancer Treatment#848236ClinicalTrials.gov
• A Clinical Research of CAR T Cells Targeting HER2 Positive Cancer#851882ClinicalTrials.gov
• Tumor autoantibodies as biomarkers for predicting ovarian cancer recurrence#153474PMC Full-Text (OAI)
• Myelonets define spatiotemporal immunosuppressive programs in ovarian cancer#651942Europe PMC
• Intraperitoneal Chemotherapy Versus Triweekly Chemotherapy#852009ClinicalTrials.gov
• High-frequency Ultrasound for Intraoperative Lymph Node Assessment in Gynecological Cancer: From Surgery to Radiomics#875220ClinicalTrials.gov
• Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer#394757ClinicalTrials.gov
• Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Persistent or Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer#844585ClinicalTrials.gov
• A Phase II Combined Modality Protocol of Debulking Surgery With HIPEC Followed by Intraperitoneal Chemotherapy for the Treatment of Recurrent Ovarian, Primary Peritoneal & Fallopian Tube Cancers#900309ClinicalTrials.gov
• MRx0518 in Patients With Solid Tumours Waiting Surgical Removal of the Tumour#845831ClinicalTrials.gov
• Ability of a Dendritic Cell Vaccine to Immunize Melanoma or Epithelial Cancer Patients Against Defined Mutated Neoantigens Expressed by the Autologous Cancer#256904ClinicalTrials.gov
• Strength Training Study for Survivors of Breast and Gynecologic Cancer#884664ClinicalTrials.gov
• Safety and Efficacy of Targeting PP2A in Ovarian Clear Cell Carcinoma Using Dostarlimab and LB-100#834295ClinicalTrials.gov
• Study of ONT-10 and Varlilumab to Treat Advanced Ovarian or Breast Cancer#853304ClinicalTrials.gov
• Bortezomib and Pegylated Liposomal Doxorubicin in BRCA Wild-type Platinum-resistant Recurrent Ovarian Cancer Patients#911421ClinicalTrials.gov
• Chemotherapy Toxicity On Quality of Life in Older Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer#834542ClinicalTrials.gov
• Disease Management Program or Usual Care in Patients With Stage III or Stage IV Lung Cancer, Pancreatic Cancer, Ovarian Cancer, or Colorectal Cancer, and Their Caregivers#864184ClinicalTrials.gov